Study on the Efficacy of Temporal Interference Stimulation (TIS) for Parkinson's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TIS.
- Who it may be relevant to
- Registry conditions: Temporal Interference Stimulation (TIS), Parkinson's Disease. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The primary objective of this clinical study is to evaluate the therapeutic efficacy of Temporal Interference Stimulation (TIS), a non-invasive deep brain stimulation technique, in patients with Parkinson's disease, and to further investigate its potential mechanisms of action. Although TIS offers lower stimulation intensity and precision compared to conventional Deep Brain Stimulation (DBS), it possesses the distinct advantage of being non-invasive. This study utilizes TIS to explore different stimulation targets analogous to those used in DBS for Parkinson's disease, thereby providing valuable insights for subsequent DBS surgical interventions. The findings will contribute preliminary exploratory evidence regarding the application of non-invasive deep brain stimulation technology in the treatment of Parkinson's disease.
Interventions
- Device TIS
Temporal Interference Stimulation
Primary outcome measures
- UPDRS-3 [Time frame: From enrollment through the 3-month follow-up]
Eligibility criteria
Inclusion criteria
- Adult males or females aged 40 years or above;
- Diagnosed with idiopathic Parkinson's disease according to the UK Brain Bank Criteria, with onset after 40 years of age;
- Previous or current dopaminergic replacement therapy (e.g., levodopa) with good response; (4) Hoehn and Yahr (H\&Y) stage 1.5-2.5;
- Ability to walk independently without assistive devices for at least 5 minutes;
- Absence of severe freezing of gait (FOG);
- Disease duration ≥2 years since diagnosis, with stable clinical condition and ability to comply with study assessments and interventions;
- Stable medication dosage for at least 4 weeks prior to the study;
- Hoehn and Yahr (H\&Y) stage 1.5-2.5;
- Signed informed consent, with the participant or legal guardian capable of understanding and willing to participate in the study.
Exclusion criteria
- Presence of other neurological disorders that may interfere with the study
- Mild or greater cognitive impairment (MoCA score ≤23)
- Orthopedic or other health conditions that may affect gait or balance
- Contraindications to MRI scanning, such as claustrophobia
- History of antipsychotic, antidepressant, or other medications that may affect dopamine levels
- Other significant psychiatric history
- Contraindications including history of epilepsy, traumatic brain injury, or implanted metal devices in the brain or heart (e.g., stimulators, pacemakers)
- History of electroconvulsive therapy
- Concurrent participation in other gait- or balance-related intervention training
- Physician-diagnosed cardiovascular risk factors for exercise.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07312279 · 2025267